INCONTESTABLE® Blog
April 19, 2024
Webinar
Advertising Self-Regulation in 2024: Q&A with NAD Vice President Laura Brett
January 30, 2024
Never miss an Insight.
Sign upFederal Circuit IP Blog
PTAB’s Implicit Claim Construction in Obviousness Analysis Constitutes Claim Construction, Even When Its Decision States It Did Not Construe Claims PTAB’s Implicit Claim Construction in Obviousness Analysis Constitutes Claim Construction, Even When Its Decision States It Did Not Construe Claims
March 21, 2024
Federal Circuit IP Blog
When to Consider Expert Testimony for Special Purpose Computer-Implemented Means-Plus-Function Claims When to Consider Expert Testimony for Special Purpose Computer-Implemented Means-Plus-Function Claims
October 20, 2023
At the PTAB Blog
Bringing Down the IPR Petition: Lack of Specification Citations Proves Fatal in Addressing Means-Plus-Function Claims Bringing Down the IPR Petition: Lack of Specification Citations Proves Fatal in Addressing Means-Plus-Function Claims
May 2, 2023
Prosecution First Blog
Federal Circuit Clarifies the Standard of Review for Invalidity Challenges Federal Circuit Clarifies the Standard of Review for Invalidity Challenges
January 13, 2023
At the PTAB Blog
Possible Defects Won’t Render Prior Art Inoperative Possible Defects Won’t Render Prior Art Inoperative
January 12, 2023
Articles
Patenting Treatments Involving Schedule I Substances Patenting Treatments Involving Schedule I Substances
October 17, 2022
Pharmaceutical OnlineProsecution First Blog
Divorced from Reality: Eastern District of Texas Calls Out “Frivolous” Arguments in Motion for Summary Judgment Divorced from Reality: Eastern District of Texas Calls Out “Frivolous” Arguments in Motion for Summary Judgment
September 30, 2022
At the PTAB Blog
When “Good Enough” Is Good Enough for Finding Obviousness When “Good Enough” Is Good Enough for Finding Obviousness
August 2, 2022
At the PTAB Blog
Past Its Peak: Freedom to Operate, Inc. Fails to Persuade PTAB to Institute Two Post-Grant Reviews for Patents Covering Psilocybin Past Its Peak: Freedom to Operate, Inc. Fails to Persuade PTAB to Institute Two Post-Grant Reviews for Patents Covering Psilocybin
July 27, 2022
Prosecution First Blog
The CCPA’s Lasting Impact on U.S. Patent Law: Part 1 The CCPA’s Lasting Impact on U.S. Patent Law: Part 1
July 8, 2022
Prosecution First Blog
Whither the CCPA? The Influence of CCPA Decisions on Anticipation Whither the CCPA? The Influence of CCPA Decisions on Anticipation
July 1, 2022
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.